The Loss of Who You Are
Every cell in your body has an identity. A fibroblast is a fibroblast. An epithelial cell is an epithelial cell. A stromal cell is a stromal cell. They express specific genes, perform specific functions, and maintain specific structural relationships with their neighbors. This is cellular identity—the molecular signature that defines what a cell is and what it does.
With age, this identity erodes. Cells begin to express genes they should not express. They adopt features of mesenchymal cells—migratory, inflammatory, fibrotic—that they were never meant to have. They lose their specialized function and become something more primitive, more plastic, and more dangerous. This is mesenchymal drift.
A 2025 study published in Cell analyzed gene expression data from over 40 human tissues and 20 diseases. The finding was pervasive: mesenchymal drift is a conserved hallmark of human aging and age-related diseases. Increased drift correlates with disease progression, reduced patient survival, and elevated mortality risk. And critically, the study showed that this drift can be reversed.
This is the frontier. The loss of cellular identity is not a one-way street. The clock can be moved backward.
What the Science Actually Shows
The Mesenchymal Drift Signature
The study analyzed gene expression data from 46 human tissues from the Genotype-Tissue Expression (GTEx) database, calculating Spearman’s ranked correlation coefficients between gene expression and age. The analysis revealed a pervasive upregulation of mesenchymal genes across multiple cell types, along with an altered composition of stromal cell populations. This is mesenchymal drift—the progressive loss of lineage identity and the adoption of mesenchymal features.
The drift is not limited to a single tissue or organ. It occurs across the body: in the lungs, liver, kidneys, heart, and blood vessels. It is associated with fibrosis (the formation of scar tissue), chronic inflammation, and organ dysfunction. And it is one of the most consistent molecular signatures of aging.
The Epithelial-Mesenchymal Transition
The mechanism of mesenchymal drift is rooted in a developmental program called the epithelial-mesenchymal transition (EMT). During embryonic development, EMT allows epithelial cells to detach from their neighbors, migrate to new locations, and differentiate into other cell types. It is essential for tissue formation and organ development.
In adult life, EMT is largely dormant. But it can be reactivated by inflammation, fibrosis, and aging. When EMT is reactivated, epithelial cells lose their cell-cell adhesion molecules (like E-cadherin), acquire migratory and invasive properties, and begin expressing mesenchymal markers (like vimentin and fibronectin). They become fibrotic, inflammatory, and dysfunctional.
The 2025 study showed that mesenchymal drift is essentially a chronic, low-grade reactivation of EMT. It is driven by the same transcription factors that drive developmental EMT—SNAI1, SNAI2, TWIST1, ZEB1, ZEB2—and it is associated with the same downstream effects: fibrosis, inflammation, and loss of tissue function.
The Reversal by Partial Reprogramming
The most striking finding of the 2025 study was that mesenchymal drift can be reversed. The Yamanaka factors—OCT4, SOX2, KLF4, and MYC (OSKM)—can reprogram fully differentiated somatic cells into a pluripotent state. Complete reprogramming erases cell identity. Partial reprogramming—the transient, cyclical expression of these factors—reverses age-related cellular damage without erasing identity.
The study showed that Yamanaka factor-induced partial reprogramming can markedly reduce mesenchymal drift before dedifferentiation and gain of pluripotency, rejuvenating the aging transcriptome at the cellular and tissue levels. The mechanism is precise: complete reprogramming of fibroblasts to a pluripotent state initiates with a process known as mesenchymal-epithelial transition (MET), where cells dedifferentiate from a mesenchymal state to an epithelial state. The study showed that Yamanaka factors can significantly mitigate mesenchymal drift by partially reprogramming cells in vitro and in vivo.
This provides mechanistic insight into the underlying beneficial effects of partial reprogramming and offers a framework for developing interventions to reverse age-related diseases.
The Science of Cellular Identity
What Maintains Identity
Cellular identity is maintained by a complex network of transcription factors, epigenetic modifications, and signaling pathways. The core principle is autoregulatory feedback loops: master transcription factors activate their own expression and the expression of downstream target genes that reinforce the cell’s identity. These loops are stabilized by epigenetic modifications—DNA methylation, histone modifications, chromatin remodeling—that lock the cell into a specific transcriptional state.
In a healthy cell, these feedback loops are robust. They resist perturbation. They maintain the cell’s identity even in the face of environmental fluctuations. But with age, the loops weaken. The epigenetic locks loosen. The cell becomes more plastic, more susceptible to drift.
What Drives Drift
The drivers of mesenchymal drift are the same as the drivers of aging itself: chronic inflammation, oxidative stress, mitochondrial dysfunction, and the accumulation of senescent cells. Each of these inputs activates signaling pathways—TGF-β, Wnt, Notch—that promote EMT and suppress epithelial identity. Over time, the balance shifts. The mesenchymal program becomes dominant. The epithelial program becomes silenced.
The 2025 study showed that suppression of key mesenchymal drift transcription factors leads to epigenetic rejuvenation. This confirms that the drift is not merely a consequence of aging but a driver of it. The loss of cellular identity is causally linked to the aging phenotype.
Interventions: What Can Be Done
Lifestyle Interventions
The lifestyle interventions that slow epigenetic aging also slow mesenchymal drift. The mechanisms overlap:
- Exercise: Reduces systemic inflammation, improves mitochondrial function, and modulates the signaling pathways (TGF-β, Wnt) that drive EMT.
- Mediterranean diet: Provides anti-inflammatory and antioxidant compounds (polyphenols, omega-3s) that suppress EMT.
- Sleep: Preserves circadian regulation of gene expression, which is disrupted in mesenchymal drift.
- Stress management: Reduces cortisol, which activates TGF-β and promotes fibrosis.
Supplements
- Omega-3 fatty acids: Reduce inflammation and fibrosis.
- Vitamin D: Regulates TGF-β signaling and suppresses EMT in some tissues.
- Curcumin: A polyphenol that inhibits TGF-β signaling and EMT in preclinical models.
- Sulforaphane: A compound found in cruciferous vegetables that activates Nrf2, an antioxidant pathway that suppresses EMT.
Emerging Medical Treatments
Partial Reprogramming: The most promising approach for reversing mesenchymal drift. The first-in-human trial of ER-100, a gene therapy delivering three Yamanaka factors (OCT4, SOX2, and KLF4, omitting the oncogenic MYC), has been initiated for age-related optic nerve conditions. The foundational study behind ER-100 demonstrated that targeting the expression of three Yamanaka factors to mouse retinal ganglion cells did not merely reverse age-related changes in gene expression; it actively regenerated mechanically damaged optic nerves.
Senolytics: Drugs that selectively clear senescent cells may reduce the inflammatory burden that drives mesenchymal drift.
Anti-fibrotic agents: Drugs that inhibit TGF-β signaling or promote matrix degradation are in development for fibrotic diseases. These may also have anti-aging effects by reducing mesenchymal drift.
The Frontier: What Comes Next
The demonstration that mesenchymal drift can be reversed by partial reprogramming has broken the conceptual barrier. The loss of cellular identity is not a one-way street. The clock can be moved backward.
But the science is still in its infancy. The first-in-human trials of partial reprogramming are evaluating safety and tolerability, not efficacy. The durability of the reversal, the optimal dosing regimen, and the applicability to different tissues and organs all remain under investigation.
The study’s authors concluded: “These findings provide mechanistic insight into the underlying beneficial effects of partial reprogramming and offer a framework for developing interventions to reverse age-related diseases using the partial reprogramming approach.”
The framework is now in place. The question is how quickly it can be translated into clinical practice.
Conclusion: The Loss of Identity Is Reversible
Mesenchymal drift is the loss of cellular identity. It is a conserved hallmark of aging and age-related diseases. It correlates with disease progression, reduced survival, and increased mortality. And it is driven by the same inflammatory and fibrotic pathways that drive aging itself.
The interventions that prevent drift are the same interventions that slow aging: exercise, the Mediterranean diet, sleep, stress management, and targeted supplements. The interventions that reverse drift are at the frontier: partial reprogramming with Yamanaka factors, senolytics, and anti-fibrotic agents.
The 2025 Cell study showed that Yamanaka factor-induced partial reprogramming can markedly reduce mesenchymal drift before dedifferentiation, rejuvenating the aging transcriptome at the cellular and tissue levels. The conceptual barrier has been broken. The clock is not a one-way ratchet.
The question is not whether you will age. The question is whether the loss of cellular identity can be reversed—and whether, at the frontier, the reprogramming factors can bring you back.
References
Lu, J. Y., Tu, B. W., Li, R., et al. (2025). Prevalent mesenchymal drift in aging and disease is reversed by partial reprogramming. Cell, *188*(21), 5895–5911.e17. https://doi.org/10.1016/j.cell.2025.07.031
Grolaux, R., Jacques, M., Jones-Freeman, B., Horvath, S., Teschendorff, A., & Eynon, N. (2026). Sex-specific nonlinear DNA methylation aging trajectories reveal biomarkers of cancer risk and inflammation. Genome Biology, *27*(1), 2. https://doi.org/10.1186/s13059-026-03952-z
Shen, X., et al. (2024). Nonlinear aging: Two major bursts of molecular change at ages 44 and 60. Nature Aging.
Wu, P., Zhao, X., Chen, Z., Huang, J., Dai, T., Zhou, J., Xiao, L., Chen, L., Zhao, R. C., & Wang, J. (2025). Identifying tipping points during healthy brain aging through single-nucleus transcriptomic analysis. Advanced Science. https://doi.org/10.1002/advs.202505779
Bischoff-Ferrari, H. A., Vellas, B., Rizzoli, R., Kressig, R. W., da Silva, J. A. P., Blauth, M., Felson, D. T., McCloskey, E. V., Watzl, B., Hofbauer, L. C., Felsenberg, D., Willett, W. C., Dawson-Hughes, B., Manson, J. E., Siebert, U., Egli, A., Theiler, R. N., Staehelin, H. B., Freystaetter, G., … & Orav, E. J. (2025). Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging, *5*, 376–385. https://doi.org/10.1038/s43587-024-00793-y
Kawamura, T., Higuchi, M., Radak, Z., et al. (2025). Exercise as a geroprotector: Focusing on epigenetic aging. Aging, *17*. https://doi.org/10.18632/aging.206278
Li, S., et al. (2026). Effects of daily multivitamin–multimineral and cocoa extract supplementation on epigenetic aging clocks in the COSMOS randomized clinical trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04239-3